Eun Yang
Stock Analyst at Jefferies
(0.45)
# 4,129
Out of 4,998 analysts
34
Total ratings
31.58%
Success rate
-26.79%
Average return
Main Sectors:
Stocks Rated by Eun Yang
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| UTHR United Therapeutics | Maintains: Buy | $315 → $432 | $424.31 | +1.81% | 8 | Sep 23, 2024 | |
| TSHA Taysha Gene Therapies | Assumes: Buy | $2 → $8 | $3.16 | +153.16% | 2 | May 14, 2024 | |
| ATXS Astria Therapeutics | Maintains: Buy | $22 → $27 | $7.36 | +266.85% | 2 | Mar 25, 2024 | |
| RLYB Rallybio | Downgrades: Hold | $7 → $1.5 | $0.56 | +169.30% | 2 | Feb 7, 2024 | |
| BBIO BridgeBio Pharma | Downgrades: Hold | $24 → $33 | $51.96 | -36.49% | 1 | Jul 18, 2023 | |
| BMEA Biomea Fusion | Downgrades: Hold | $36 → $28 | $2.06 | +1,259.22% | 2 | Jun 26, 2023 | |
| ELVN Enliven Therapeutics | Initiates: Buy | $27 | $20.30 | +33.00% | 1 | Mar 29, 2023 | |
| GNSS Genasys | Maintains: Outperform | $6 → $7 | $2.24 | +212.50% | 1 | Feb 10, 2023 | |
| CVAC CureVac | Upgrades: Buy | n/a | $5.35 | - | 2 | Jan 9, 2023 | |
| PRME Prime Medicine | Initiates: Buy | $25 | $5.32 | +369.92% | 1 | Nov 14, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $105,000 → $15,000 | $3.83 | +391,544.91% | 1 | Sep 22, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $25 | $2.20 | +1,036.36% | 1 | Nov 2, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $35 | $24.40 | +43.44% | 1 | Jun 22, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $200 → $220 | $273.97 | -19.70% | 3 | Jul 27, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Assumes: Hold | $310 | $138.52 | +123.79% | 3 | Jul 11, 2017 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Assumes: Hold | $80 | $112.62 | -28.96% | 3 | Jul 11, 2017 |
United Therapeutics
Sep 23, 2024
Maintains: Buy
Price Target: $315 → $432
Current: $424.31
Upside: +1.81%
Taysha Gene Therapies
May 14, 2024
Assumes: Buy
Price Target: $2 → $8
Current: $3.16
Upside: +153.16%
Astria Therapeutics
Mar 25, 2024
Maintains: Buy
Price Target: $22 → $27
Current: $7.36
Upside: +266.85%
Rallybio
Feb 7, 2024
Downgrades: Hold
Price Target: $7 → $1.5
Current: $0.56
Upside: +169.30%
BridgeBio Pharma
Jul 18, 2023
Downgrades: Hold
Price Target: $24 → $33
Current: $51.96
Upside: -36.49%
Biomea Fusion
Jun 26, 2023
Downgrades: Hold
Price Target: $36 → $28
Current: $2.06
Upside: +1,259.22%
Enliven Therapeutics
Mar 29, 2023
Initiates: Buy
Price Target: $27
Current: $20.30
Upside: +33.00%
Genasys
Feb 10, 2023
Maintains: Outperform
Price Target: $6 → $7
Current: $2.24
Upside: +212.50%
CureVac
Jan 9, 2023
Upgrades: Buy
Price Target: n/a
Current: $5.35
Upside: -
Prime Medicine
Nov 14, 2022
Initiates: Buy
Price Target: $25
Current: $5.32
Upside: +369.92%
Sep 22, 2022
Maintains: Buy
Price Target: $105,000 → $15,000
Current: $3.83
Upside: +391,544.91%
Nov 2, 2021
Initiates: Buy
Price Target: $25
Current: $2.20
Upside: +1,036.36%
Jun 22, 2021
Initiates: Buy
Price Target: $35
Current: $24.40
Upside: +43.44%
Jul 27, 2018
Maintains: Buy
Price Target: $200 → $220
Current: $273.97
Upside: -19.70%
Jul 11, 2017
Assumes: Hold
Price Target: $310
Current: $138.52
Upside: +123.79%
Jul 11, 2017
Assumes: Hold
Price Target: $80
Current: $112.62
Upside: -28.96%